All GLG News Analyses Filed Under: Endocrinology

This article is important as it highlights the many benefits of the Niacin drugs.  It describes how MK-0524 may significantly increase adherence as it reduces the side effect of flushing.  This article describes preliminary trials with the new formulation clearly showing a reduction in the...

The question implies that giving less erythropoietin (Epo) preparations will increase the suffering of patients with renal failure due to not having their hemoglobins (Hgb) returned to "normal." WRONG. All that is being advised is that clinicians be careful and not increase the Hgb to normal...

ESA agents have drastically changed management of anemiaESA agents have gotten a bad reputation

"There was no difference in lipid response when MK-0524 with ERN was compared to treatment with ERN alone." However.......

As a physician who tries to use niaspan in pts to lower trigs and raise HDL. I have a hard time getting pts to tolerate the drug. If this new drug works, it will be very helpful in my practice.

Important is not the right word for the ACOG article in question. More important is a sound and solid scientific debate about the issue.

The article represents a very limited snapshot of the bioidentical hormone therapy market potential. Industry will have to push the FDA to perform its perfunctory duties assuring safety and efficacy of the bioidentical hormone therapies.     

- Flushing and pruritis associated with niacin is common and may be very uncomfortable leading to discontinuation of drug and usually substitution with statin- This drug would compete with statins, not Niaspan

ACOG raises very important questions on "bioidentical" hormones.

Rimonabant is a novel CB1 inhibitor which blocks the endogenous endocannibinoid receptor that leads to overeating.Rimonabant has been shown to cause a much greater weight loss than previous medications without any of the serious side effects seen with them to date.These results have been sustained for...